Restriction of CLPTM1L surface expression to stem cell populations14,21 and tumor cells presents the potential to target quiescent residual tumor cells and to eliminate inherent or acquired resistance to multiple chemotherapeutic drugs. The gene discussed is CLPTM1L; the disease is neoplasm.